AVP and neoplasm: ADH-503, a CD11b agonist, is indeed able to repolarise TAM towards an anti-tumour phenotype and to enhance dendritic cell responses which in turn support T cell-mediated tumour restriction and synergism with ICT in pancreatic cancer, a tumour in which ICT does not show any benefit when employed as single agent [67].